Calcitonin effects on patients with pertrochanteric fractures. A four year prospective randomized clinical trial

Calcitonin effects on patients with pertrochanteric fractures. A four year prospective randomized clinical trial

Karachalios, Th

Purpose: The efficacy of nasal salmon calcitonin (CT) in preventing bone loss after a hip fracture and in reducing the incidence of further contralateral hip fractures was evaluated.

Material and Methods: Fifty women aged 70-80 years who sustained a pertrochanteric fracture were randomly allocated to Group A (200 IU of nasal salmon calcitonin daily for three months) and Group B (placebo). Biochemical bone markers (1st, 7th, 15th, 45th and 90th day post injury) and bone mineral density of the lumbar spine and the intact contralateral hip (4th and 90th postoperative day, and one year after the fracture) were measured.

Results: Patients in the calcitonin group showed statistically significantly higher total (p

Conclusion: Nasal salmon calcitonin prevented early bone loss in these patients and may have a protective role on the occurrence of a new fracture of the contralateral hip in the same patient.

Th. Karachalios, G. Lyritis, J. Kaloudis, K. Bargiotas, KN. Malizos

Laboratory for the Research of Musculoskeletal System “Th. Garofalidis”, University of Athens

University of Thessaly, Dept of Orthopaedics, University Hospital, Larisa

Copyright British Editorial Society of Bone & Joint Surgery 2003

Provided by ProQuest Information and Learning Company. All rights Reserved